The estimated Net Worth of Sujal Shah is at least $15.8 Million dollars as of 13 March 2024. Mr. Shah owns over 139,119 units of Cymabay Therapeutics Inc stock worth over $13,208,642 and over the last 10 years he sold CBAY stock worth over $0. In addition, he makes $2,556,470 as President, Chief Executive Officer, and Director at Cymabay Therapeutics Inc.
Sujal has made over 15 trades of the Cymabay Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 139,119 units of CBAY stock worth $656,642 on 13 March 2024.
The largest trade he's ever made was exercising 139,119 units of Cymabay Therapeutics Inc stock on 13 March 2024 worth over $656,642. On average, Sujal trades about 17,742 units every 104 days since 2015. As of 13 March 2024 he still owns at least 406,670 units of Cymabay Therapeutics Inc stock.
You can see the complete history of Mr. Shah stock trades at the bottom of the page.
Sujal Shah is President, Chief Executive Officer, Director of the Company. Mr. Shah previously served as our Interim President and Chief Executive Officer from March 2017 to November 2017 and as our Chief Financial Officer from December 2013 to March 2017. Prior to that he served as a consultant and acting Chief Financial Officer for us from June 2012 to December 2013. From 2010 to 2012, Mr. Shah served as Director, Health Care Investment Banking for Citigroup Inc., where he was responsible for managing client relationships and executing strategic and financing related transactions for clients focused in life sciences. From 2004 to 2010 Mr. Shah was employed with Credit-Suisse, last serving in the capacity as Vice President, Health Care Investment Banking Group. Mr. Shah received a M.B.A. from Carnegie Mellon University—Tepper School of Business and M.S. and B.S. degrees in Biomedical Engineering from Northwestern University. Mr. Shah currently serves on the Executive Advisory Board of the Chemistry Life Processes Institute at Northwestern University. Because of his extensive experience executing strategic and financing transactions both as an advisor and as an operator in the biopharmaceutical industry, his foundational scientific training, and his intimate knowledge of our company, we believe he is able to make valuable contributions to the Board.
As the President, Chief Executive Officer, and Director of Cymabay Therapeutics Inc, the total compensation of Sujal Shah at Cymabay Therapeutics Inc is $2,556,470. There are no executives at Cymabay Therapeutics Inc getting paid more.
Sujal Shah is 46, he's been the President, Chief Executive Officer, and Director of Cymabay Therapeutics Inc since 2017. There are 16 older and no younger executives at Cymabay Therapeutics Inc. The oldest executive at Cymabay Therapeutics Inc is Robert Wills, 66, who is the Independent Chairman of the Board.
Sujal's mailing address filed with the SEC is C/O CYMABAY THERAPEUTICS, INC., 7601 DUMBARTON CIRCLE, FREMONT, CA, 94555.
Over the last 10 years, insiders at Cymabay Therapeutics Inc have traded over $17,635,452 worth of Cymabay Therapeutics Inc stock and bought 2,170,647 units worth $6,725,086 . The most active insiders traders include Capital Advisors Llc Aghaza..., Kurt Von Emster, and Carl Goldfischer. On average, Cymabay Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $1,796,241. The most recent stock trade was executed by Sujal Shah on 13 March 2024, trading 139,119 units of CBAY stock currently worth $656,642.
cymabay therapeutics is a clinical-stage biopharmaceutical company located in the san francisco bay area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. we are committed to developing breakthrough medicines that improve the lives of patients and their families. cymabay was seeded with the assets from an earlier metabolic disease company in which more than $120m was invested to produce a robust pipeline.
Cymabay Therapeutics Inc executives and other stock owners filed with the SEC include: